Medium-term results of heart transplantation using older donor organs. 2000

M Loebe, and E V Potapov, and M Hummel, and Y Weng, and W Bocksch, and R Hetzer
Deutsches Herzzentrum Berlin, Berlin, Germany. loebe@dhzb.de

BACKGROUND Donor heart shortage has necessitated the expansion of the donor pool by the use of older hearts. METHODS In a 13-year period, 1,070 heart transplants were performed in 1,035 adults at the German Heart Institute Berlin. We divided the patients into 3 groups: Group I, donor age <35 years (n = 524); Group II, donor age 35 to 50 years (n = 379); Group III, donor age >50 years (n = 167). We analyzed post-operative mortality (up to 30 days), cumulative survival rates, cardiac dependent morbidity, and changes in the left/right ventricular ejection fraction as well as freedom from cytomegalovirus infection and freedom from acute rejection episodes grade >/= 2 (International Society for Heart and Lung Transplantation). We also calculated the rate of cardiac interventions per patient in the groups. RESULTS Recipients in Group III were significantly older, compared with Groups I and II. The post-operative mortality was 16.8% in Group I, 29.8% in Group II, and 23.4% in Group III. The differences were significant (p = 0. 00001) between Group I and Group II. The long-term cumulative survival rates were significantly better in Group I when compared with Groups II and III (p < 0.00001, p = 0.014), but it did not differ between Groups II and III (p = 0.18). However, cardiac morbidity in Groups I and II was significantly lower when compared with Group III (p = 0.0009, p = 0.037). Mean left and right ventricular ejection fraction was >55% and did not significantly change in groups for up to 10 years. Freedom from cytomegalovirus infection was not significantly different between Groups II and III (p = 0.09). Significantly fewer percutaneous transluminal coronary angioplasties were performed in Group I, but comparable numbers were carried out in Groups II and III (p = 0.53). For retransplantation a similar situation occurred. CONCLUSIONS We did not find significant differences in the mid-term follow-up between patients who received hearts from 35- to 50-year-old donors and from those who had received hearts from donors >50 years, despite increased cardiac morbidity in Group III. Close monitoring of the coronary situation after heart transplantation and expanded indications for revascularization in Group III makes heart transplantation with older hearts a suitable option to save the lives of patients in end-stage heart failure.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft
D006331 Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities. Cardiac Disorders,Heart Disorders,Cardiac Diseases,Cardiac Disease,Cardiac Disorder,Heart Disease,Heart Disorder
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014019 Tissue Donors Individuals supplying living tissue, organs, cells, blood or blood components for transfer or transplantation to histocompatible recipients. Organ Donors,Donors,Ovum Donors,Semen Donors,Transplant Donors,Donor,Donor, Organ,Donor, Ovum,Donor, Semen,Donor, Tissue,Donor, Transplant,Donors, Organ,Donors, Ovum,Donors, Semen,Donors, Tissue,Donors, Transplant,Organ Donor,Ovum Donor,Semen Donor,Tissue Donor,Transplant Donor

Related Publications

M Loebe, and E V Potapov, and M Hummel, and Y Weng, and W Bocksch, and R Hetzer
January 1992, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation,
M Loebe, and E V Potapov, and M Hummel, and Y Weng, and W Bocksch, and R Hetzer
January 2001, Transplantation proceedings,
M Loebe, and E V Potapov, and M Hummel, and Y Weng, and W Bocksch, and R Hetzer
November 1990, The American review of respiratory disease,
M Loebe, and E V Potapov, and M Hummel, and Y Weng, and W Bocksch, and R Hetzer
December 1997, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation,
M Loebe, and E V Potapov, and M Hummel, and Y Weng, and W Bocksch, and R Hetzer
January 1991, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation,
M Loebe, and E V Potapov, and M Hummel, and Y Weng, and W Bocksch, and R Hetzer
August 2019, The Journal of thoracic and cardiovascular surgery,
M Loebe, and E V Potapov, and M Hummel, and Y Weng, and W Bocksch, and R Hetzer
July 2004, Organogenesis,
M Loebe, and E V Potapov, and M Hummel, and Y Weng, and W Bocksch, and R Hetzer
June 1987, Acta ophthalmologica,
M Loebe, and E V Potapov, and M Hummel, and Y Weng, and W Bocksch, and R Hetzer
March 2007, Transplantation,
M Loebe, and E V Potapov, and M Hummel, and Y Weng, and W Bocksch, and R Hetzer
October 2018, Clinical transplantation,
Copied contents to your clipboard!